This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (463) Cancer Survivorship (200) Children and Young People With Cancer, Pediatric Oncology (42) Precision Medicine and Genetics (37) Cardiology (64)

Published on in Vol 11 , No 2 (2022) :February

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/27898, first published .
Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Authors of this article:

Oliver Zolk 1 Author Orcid Image ;   Annika von dem Knesebeck 2 Author Orcid Image ;   Norbert Graf 3 Author Orcid Image ;   Thorsten Simon 4 Author Orcid Image ;   Barbara Hero 4 Author Orcid Image ;   Hashim Abdul-Khaliq 5 Author Orcid Image ;   Mohamed Abd El Rahman 5 Author Orcid Image ;   Claudia Spix 6 Author Orcid Image ;   Benjamin Mayer 7 Author Orcid Image ;   Susanne Elsner 8 Author Orcid Image ;   Judith Gebauer 9 Author Orcid Image ;   Thorsten Langer 10 Author Orcid Image
Article Authors Cited by (1) Tweetations (4) Metrics

Journals

  1. Nyangwara V, Mazhindu T, Chikwambi Z, Masimirembwa C, Campbell T, Borok M, Ndlovu N. Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients. British Journal of Clinical Pharmacology 2023 View